SCHEMBL4135342

SCHEMBL4135342

CC(C)c1csc(NC(=O)C(F)(F)F)c1C(=O)Nc1ccc(Cl)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.49
RAB9A P51151 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
NPC1 O15118 4/20 0.43
TSHR P16473 3/20 0.43
TP53 P04637 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
PTK2 Q05397 1/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2C9 P11712 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147196 0.86 ANO1 (0.53) SMN1; SMN2TP53ALDH1A1HTTMAPK1
SCHEMBL4141063 0.74 ABCC1 (0.56) RAB9ASMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL4150347 0.73 ANO1 (0.41) SMN1; SMN2TP53MAPTANO1
SCHEMBL4134763 0.73 ANO1 (0.74) SMN1; SMN2TP53ALDH1A1MAPTANO1
SCHEMBL4149999 0.72 KMT2A (0.50) RAB9ASMN1; SMN2TSHRTP53HTT
SCHEMBL4141429 0.71 ANO1 (0.51) BRD4SMN1; SMN2TP53MAPTANO1
SCHEMBL4150055 0.69 ABCC1 (0.40) TP53ALDH1A1CYP2C19CYP2C9TDP1
SCHEMBL8388485 0.68 ABCC1 (0.36) RAB9ASMN1; SMN2NPC1TP53ALDH1A1
SCHEMBL4277493 0.68 F10 (0.55) BRD4RAB9ASMN1; SMN2NPC1TSHR
SCHEMBL23565304 0.67 L3MBTL1 (0.66) BRD4RAB9ASMN1; SMN2NPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL BRD4 558/4885RAB9A 3003/4885SMN1; SMN2 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.